Frontlight ResearchEarly access
Taking people in ItalyPhase 3
Testing thyroid protection during radiation in children with medulloblastoma or lymphoma
Tests whether thyroid hormone suppression during radiation lowers later underactive thyroid in children.
Key facts
- Who runs it
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Where
- Milan, ItalySee the site
- Registry title
- Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 65 people, planned
- Started
- 13 Dec 2021
- Expected to end
- 28 Dec 2029
- Type of study
- Interventional
- Record updated
- 23 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with medulloblastoma, Hodgkin lymphoma or non-Hodgkin lymphoma who are about to have radiotherapy that includes the thyroid gland, and who have no earlier thyroid underactivity.
- Sex
- All sexes can join.
- Disease stage
- Medulloblastoma (any stage, any biological risk), Hodgkin lymphoma or non-Hodgkin lymphoma. Radiotherapy planned to include the thyroid gland tissue.
- Earlier treatment
- Must not yet have had radiotherapy that included the thyroid gland. Must not have had thyroid underactivity (primary or secondary hypothyroidism) before.
Main reasons for not taking part
- Radiotherapy including the thyroid gland already given
- Previous primary or secondary hypothyroidism
- No signed consent
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Any patient with medulloblastoma, Hodgkin/non-Hodgkin Lymphoma BEFORE RADIOTHERAPY (RT) PLANNING INCLUDING THYROID PARENCHYMA without previous primary or secondary hypothyroidism
- Written informed consent prior to any study-specific analysis and/or data collection
Who cannot take part
- Any patient with medulloblastoma, Hodgkin/non-Hodgkin Lymphoma after radiotherapy including thyroid parenchyma
- Not signed consent
Where in Italy
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyTaking people
About the trial
What the trial wants to find out
To evaluate if the incidence of hypothyroidism after radiation therapy in medulloblastoma, Hodgkin and non-Hodgkin lymphomas can be reduced by TSH suppression during irradiation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021
- Plain-language title
- Testing thyroid protection during radiation in children with medulloblastoma or lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 23 September 2026